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ARTICLE
Components of genetic associations across 2,138
phenotypes in the UK Biobank highlight adipocyte
biology
Yosuke Tanigawa 1,14, Jiehan Li2,3,14, Johanne M. Justesen1,2,4, Heiko Horn 5,6, Matthew Aguirre 1,7,
Christopher DeBoever1,8, Chris Chang9, Balasubramanian Narasimhan1,10, Kasper Lage5,6,11, Trevor Hastie1,10,
Chong Y. Park2, Gill Bejerano 1,7,12,13, Erik Ingelsson 2,3,14 & Manuel A. Rivas 1,14
Population-based biobanks with genomic and dense phenotype data provide opportunities for
generating effective therapeutic hypotheses and understanding the genomic role in disease
predisposition. To characterize latent components of genetic associations, we apply trun-
cated singular value decomposition (DeGAs) to matrices of summary statistics derived from
genome-wide association analyses across 2,138 phenotypes measured in 337,199 White
British individuals in the UK Biobank study. We systematically identify key components of
genetic associations and the contributions of variants, genes, and phenotypes to each
component. As an illustration of the utility of the approach to inform downstream experi-
ments, we report putative loss of function variants, rs114285050 (GPR151) and rs150090666
(PDE3B), that substantially contribute to obesity-related traits and experimentally demon-
strate the role of these genes in adipocyte biology. Our approach to dissect components of
genetic associations across the human phenome will accelerate biomedical hypothesis
generation by providing insights on previously unexplored latent structures.
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Human genetic studies have been profoundly successful atidentifying regions of the genome contributing to diseaserisk1,2. Despite these successes, there are challenges to
translating ﬁndings to clinical advances, much due to the wide-
spread pleiotropy and extreme polygenicity of complex traits,
which are the presence of genetic effects of a variant across
multiple phenotypes and multiple variants across a single phe-
notype3–5. In retrospect, this is not surprising given that most
common diseases are multifactorial. However, it remains unclear
exactly which factors, acting alone or in combination, contribute
to disease risk and how those factors are shared across diseases.
With the emergence of sequencing technologies, we are increas-
ingly able to pinpoint alleles, possibly rare and with large effects,
which may aid in therapeutic target prioritization6–13. Further-
more, large population-based biobanks, such as the UK Biobank,
have aggregated data across tens of thousands of phenotypes14.
Thus, an opportunity exists to characterize the phenome-wide
landscape of genetic associations across the spectrum of genomic
variation, from coding to non-coding, and rare to common.
Singular value decomposition (SVD), a mathematical approach
developed by differential geometers15, can be used to combine
information from several (likely) correlated vectors to form basis
vectors, which are guaranteed to be orthogonal and to explain
maximum variance in the data, while preserving the linear
structure that helps interpretation. In the ﬁeld of human genetics,
SVD is routinely employed to infer genetic population structure
by calculating principal components using the genotype data of
individuals16.
To address the pervasive polygenicity and pleiotropy of com-
plex traits, we propose an application of truncated SVD (TSVD),
a reduced rank approximation of SVD17–19, to characterize the
underlying (latent) structure of genetic associations using sum-
mary statistics computed for 2,138 phenotypes measured in the
UK Biobank population cohort14. We apply our approach,
referred to as DeGAs — decomposition of genetic associations —
to assess associations among latent components, phenotypes,
variants, and genes. We highlight its application to body mass
index (BMI), myocardial infarction (MI), and gallstones, moti-
vated by high polygenicity in anthropometric traits, global bur-
den, and economic costs, respectively. We assess the relevance of
the inferred key components through GREAT genomic region
ontology enrichment analysis20,21 and functional experiments.
The results from DeGAs applied to protein-truncating variants
(PTV) dataset indicate strong associations of targeted PTVs to
obesity-related traits, while phenome-wide association analyses
(PheWAS) uncover the differential region-speciﬁc regulation of
our top candidates in fat deposition. For these reasons, we
prioritize adipocytes as our experimental model system for the
follow-up functional studies of our candidate genes. Given that
the roles of adipocytes in regulating metabolic ﬁtness have been
established at both local and systemic levels of pathology asso-
ciated with obesity, it is likely that the differentiation and function
of adipocytes may shape the effects of our candidate genes at the
cellular and molecular level.
Results
DeGAs method overview. We generated summary statistics by
performing genome-wide association studies (GWAS) of 2,138
phenotypes from the UK Biobank (Fig. 1a, Supplementary Table
1, Supplementary Data 1). We performed variant-level quality
control, which includes linkage-disequilibrium (LD) pruning and
removal of variants in the MHC region, to focus on 235,907
variants for subsequent analyses. Given the immediate biological
consequence, subsequent downstream implications, and medical
relevance of coding variants and predicted protein-truncating
variants (PTVs), commonly referred to as loss-of-function
variants12,22,23, we performed separate analyses on three variant
sets: (1) all directly-genotyped variants, (2) coding variants, and
(3) PTVs (Supplementary Fig. 1). To eliminate unreliable esti-
mates of genetic associations, we selected associations with p-
values < 0.001, and standard error of beta value or log odds ratio
of less than 0.08 and 0.2, respectively, for each dataset. The Z-
scores of these associations were aggregated into a genome- and
phenome-wide association summary statistic matrix W of size
N ×M, where N and M denote the number of phenotypes and
variants, respectively. N and M were 2,138 and 235,907 for the
“all” variant group; 2,064 and 16,135 for the “coding” variant
group; and 628 and 784 for the PTV group. The rows and col-
umns of W correspond to the GWAS summary statistics of a
phenotype and the phenome-wide association study (PheWAS)
of a variant, respectively. Given its computational efﬁciency
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Fig. 1 Illustrative study overview. a Summary of the UK Biobank genotype and phenotype data used in the study. We included White British individuals and
analyzed LD-pruned and quality-controlled variants in relation to 2,138 phenotypes with a minimum of 100 individuals as cases (binary phenotypes) or
non-missing values (quantitative phenotypes) (Supplementary Table 1, Supplementary Data 1). b Truncated singular value decomposition (TSVD) applied
to decompose genome- and-phenome-wide summary statistic matrix W to characterize latent components. U, S, and V represent resulting matrices of
singular values and vectors. c Decomposition of Genetic Associations (DeGAs) characterizes latent genetic components, which are represented as
different colors on the palette, with an unsupervised learning approach — TSVD, followed by identiﬁcation of the key components for each phenotype of
our interest (painting phenotypes with colors) and annotation of each of the components with driving phenotypes, variants, and genes (ﬁnding the
meanings of colors). d We used the squared cosine score and the contribution score, to quantify compositions and biomedical relevance of latent
components. e We applied the genomic region enrichment analysis tool (GREAT) for biological characterization of each component and performed
functional experiments focusing on adipocyte biology
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compared to the vanilla SVD, we applied TSVD to each matrix
and obtained a decomposition into three matricesW=USVT (U:
phenotype, S: variance, V: variant). This reduced representation
of K= 100 components altogether explained 41.9% (all), 62.8%
(coding) and 75.5% (PTVs) of the variance in the original sum-
mary statistic matrices (Fig. 1b, Methods, Supplementary Fig. 2).
In DeGAs framework, we employ these latent components
characterized from a densely phenotyped population-based cohort
to investigate the genetics of common complex traits (Fig. 1c). To
characterize each latent component and identify the relevant
component given a phenotype, a gene, or a variant, or vice versa,
we deﬁned ﬁve different quantitative scores: phenotype squared
cosine score, phenotype and variant contribution score, variant
contribution score, and gene contribution score. The squared
cosine scores quantify the relative importance of component for a
given phenotype or gene, and are deﬁned based on the squared
distance of a component from the origin on the latent space.
Contribution scores quantify relative importance of a phenotype,
variant, or gene to a given component and is deﬁned based on the
squared distance of a phenotype, variant, or gene from the origin24
(Fig. 1d, Methods). Using scores, DeGAs identiﬁes the key latent
components for a given complex trait and annotated them with
the driving phenotypes, genes, and variants (Fig. 1c, Methods). We
performed biological characterization of DeGAs components with
the genomic region enrichment analysis tool (GREAT)20,21
followed by functional experiments in adipocytes (Fig. 1e).
Characterization of DeGAs latent components. The PCA plots
show the projection of phenotypes and variants onto DeGAs
latent components. (Fig. 2a, b). For the variant PCA plot, we
overlay biplot annotation as arrows to interpret the direction of
the components (Fig. 2b, Methods). Overall, we ﬁnd that the ﬁrst
ﬁve DeGAs components can be attributed to: 1) fat-free mass that
accounts for the “healthy part” of body weight25 (32.7%, Sup-
plementary Table 2) and two intronic variants in FTO
(rs17817449: contribution score of 1.15% to PC1, rs7187961:
0.41%); and a genetic variant proximal to AC105393.1
(rs62106258: 0.46%); 2) fat mass and percentage measurements
(61.5%) and the same three FTO and AC105393.1 variants
(rs17817449: 0.97%, rs7187961: 0.28%, rs62106258: 0.27%); 3)
bioelectrical impedance measurements (38.7%), a standard
method to estimate body fat percentage26,27, and genetic variants
proximal to ACAN (rs3817428: 0.64%), ADAMTS3 (rs11729800:
0.31%), and ADAMTS17 (rs72770234: 0.29%); 4) eye meridian
measurements (80.9%), and two intronic variants in WNT7B
(rs9330813: 5.73%, rs9330802: 1.14%) and a genetic variant
proximal to ATXN2 (rs653178: 0.96%); and 5) bioelectrical
impedance and spirometry measures (45.4% and 26.0%, respec-
tively) and genetic variants proximal to FTO (rs17817449: 0.17%),
ADAMTS3 (rs11729800: 0.11%), and PSMC5 (rs13030: 0.11%)
(Fig. 2c, d, Supplementary Data 2).
To highlight the ability of DeGAs to capture related sets of
phenotypes, genes, and variants in genetic associations, we also
applied TSVD to the missing-value imputed and Z-score
transformed phenotype matrix and characterized the ﬁrst 100
latent components (Methods). Using the individual and pheno-
type PCA plots, we found a fewer number of components that
explains most of the variance and several phenotypes, such as
trafﬁc intensity of the nearest major road and creatinine
(enzymatic) in urine, are dominantly driving the top phenotypic
PCs (Supplementary Figs. 4, 5). We applied GWAS for each of
the decomposed phenotypes (Supplementary Fig. 6). Through the
genetic correlation analysis with the derived summary statistics,
we found non-zero genetic correlations among the phenotypic
PCs (Supplementary Figs. 7, 8).
DeGAs application to BMI, MI, and gallstones. To illustrate the
application of DeGAs in characterizing the genetics of complex
traits, we selected three phenotypes, BMI, MI, and gallstones,
given the large contribution of anthropometric traits on the ﬁrst
ﬁve components, that ischemic heart diseases is a leading global
fatal and non-fatal burden, and that gallstones is a common
condition with severe pain and large economic costs where
polygenic risk factors are largely unknown28,29. We identiﬁed the
top three key components for these three phenotypes with DeGAs
using the “all” variants dataset.
For BMI, we ﬁnd that the top three components of genetic
associations (PC2, PC1, and PC30) altogether explained over 69%
of the genetic associations (47, 18, and 4%, respectively,
Supplementary Fig. 3a). The top two components (PC2 and
PC1) corresponded to components of body fat (PC2) and fat-free
mass measures (PC1), as described above. PC30 was driven by fat
mass (28.7%) and fat-free mass (6.8%), but also by non-
melanoma skin cancer (7.72%) — linked to BMI in epidemio-
logical studies30 — and childhood sunburn (7.61%) (Fig. 3a,
Supplementary Data 2).
For MI, a complex disease inﬂuenced by multiple risk factors31,
we found that the top components were attributed to genetics of
lipid metabolism (PC22, high-cholesterol, statin intake, and
APOC1), alcohol intake (PC100), and sleep duration and food
intake (PC83, 25.2%) that collectively corresponded to 36% of the
genetic associations (Fig. 3a, Supplementary Figs. 3b, 9, 10,
Supplementary Data 2).
Cholelithiasis is a disease involving the presence of gallstones,
which are concretions that form in the biliary tract, usually in the
gallbladder32. We found that the top components contributing to
gallstones corresponded to associations with fresh fruit (PC72)
and water intake (PC64), as well as bioelectrical impedance of
whole body (PC67) corresponding to 51% of genetic associations
altogether (Fig. 3a, Supplementary Figs. 3c, 9, 11, Supplementary
Data 2). We conﬁrmed the robustness of these results with
respect to the selection of number of components, K (Methods,
Supplementary Figs. 12–16).
Biological characterization of DeGAs components. To provide
biological characterization of the key components, we applied the
genomic region enrichment analysis tool (GREAT)20,21 to dissect
the biological relevance of the identiﬁed components with both
coding and non-coding variants. Given the coverage of the
manually curated knowledge of mammalian phenotypes, we
focused on the mouse genome informatics (MGI) phenotype
ontology and set p= 5 × 10−6 as the Bonferroni-corrected sta-
tistical signiﬁcance threshold (Method)33. For each key compo-
nent, we applied GREAT and found an enrichment for the mouse
phenotypes consistent with the phenotypic description of our
diseases of interest20,21. The top component for BMI, identiﬁed as
the body fat measures component (PC2), showed enrichment of
several anthropometric terms including abnormally short feet
(brachypodia) (MP:0002772, binomial fold= 9.04, p= 1.3 × 10−23),
increased birth weight (MP:0009673, fold= 6.21, p= 1.3 ×
10−11), and increased body length (MP:0001257, binomial fold=
3.01, p= 1.3 × 10−36) (Fig. 3b, Supplementary Data 3). For MI,
we found enrichment of cardiac terms, such as artery occlusion
(PC22, MP:0006134, fold= 15.86, p= 1.14 × 10−25) and aortitis
(PC22, MP:0010139, aorta inﬂammation, fold= 9.36, p= 3.41 ×
10−31) (Supplementary Fig. 17, Supplementary Data 4). Similarly,
for gallstones, the top enrichment was for abnormal circulating
phytosterol level (PC72, MP:0010075, fold= 11.54, p= 5.51 ×
10−11), which is known to be involved in gallstone development34
(Supplementary Fig. 18, Supplementary Data 5).
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To test the speciﬁcity of the enriched ontology terms while
considering the correlation structure within ontology terms, we
took the top ﬁve enriched terms for each DeGAs component,
obtained the list of genes annotated with these top terms, and
measured their pairwise gene set similarity across 100 DeGAs
components using Jaccard index (Methods). Jaccard index is a set
similarity measure ranges between zero and one, where one
means the complete match and zero means complete disjoint of
the two sets. We found the median of the pairwise similarity to be
0.029 (Supplementary Fig. 19).
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Coding and protein-truncating variants. Given the challenges
with interpreting genetic associations across thousands of possi-
bly correlated phenotypes and diverse variant functional cate-
gories, we applied DeGAs to coding variant-phenotype
associations and PTV associations. For the coding dataset, we
identiﬁed PC2 and PC1 as the top two key components for BMI,
with 51% and 14% of phenotype squared contribution scores,
respectively (Supplementary Fig. 20). The major drivers of these
two components include fat mass measurements (55.2% of phe-
notype contribution score for PC2), fat-free mass measurements
(33.3%, PC1), genetic variants on MC4R (3.7% gene contribution
score for PC2), and ZFAT (3.4% gene contribution score for PC1)
(Supplementary Figs. 21–22, Supplementary Data 2).
Predicted PTVs are a special class of protein-coding genetic
variants with possibly strong effects on gene function9,12,22,35.
More importantly, strong effect PTV-trait associations can
uncover promising drug targets, especially when the direction
of effect is consistent with protection of human disease. Using the
PTV dataset, we identiﬁed PC1 and PC3 as the top two key
components for BMI, with 28% and 12% of phenotype squared
contribution scores, respectively (Supplementary Fig. 23). The
major drivers of PC1 were weight-related measurements,
including left and right leg fat-free mass (5.0% and 3.7% of
phenotype contribution score for PC1, respectively), left and right
leg predicted mass (4.9% each), weight (4.6%), and basal
metabolic rate (4.6%), whereas the drivers of PC3 included
standing height (13.7%), sitting height (8.1%), and high
reticulocyte percentage (6.4%) (Fig. 4a, Supplementary Data 2).
Top contributing PTVs to PC1 included variants in PDE3B
(19.0%), GPR151 (12.3%), and ABTB1 (8.5%), whereas PC3 was
driven by PTVs on TMEM91 (8.6%), EML2-AS1 (6.7%), and
KIAA0586 (6.0%) (Fig. 4b, Supplementary Data 2).
Based on stop-gain variants in GPR151 (rs114285050) and
PDE3B (rs150090666) being key contributors to the top two
components of genetic associations for PTVs and BMI (Fig. 4c),
we proceeded to detailed phenome-wide association analysis
(PheWAS) assessing associations of these PTVs with anthropo-
metric phenotypes. PheWAS analysis of these variants conﬁrmed
strong associations with obesity-related phenotypes including
waist circumference (GPR151, marginal association beta=
−0.065, p= 2.5 × 10−8), whole-body fat mass (GPR151, beta=
−0.069, p= 1.4 × 10−7), trunk fat mass (GPR151, beta=−0.071,
p= 1.5 × 10−7), hip circumference (PDE3B, beta= 0.248, p=
1.8 × 10−11), right leg fat-free mass (PDE3B, beta= 0.129, p=
4.2 × 10−8) and body weight (PDE3B, beta= 0.177, p= 4.6 ×
10−8) (Fig. 4d, Supplementary Fig. 24, Supplementary Tables 3-4).
Among 337,199 White British individuals, we found 7,560
heterozygous and 36 homozygous carriers of the GPR151 variant
and 947 heterozygous carriers of PDE3B variants. To assess the
effect of the PTVs on BMI, a commonly-used measure of obesity,
we performed univariate linear regression analysis with age, sex,
and the ﬁrst four genetic PCs as covariates and found that
heterozygous and carriers of GPR151 PTVs showed 0.324 kg m−2
lower BMI than the average UK Biobank participant (p= 4.13 ×
10−7). We did not ﬁnd evidence of association with homozygous
carriers (n= 28; p= 0.665), presumably due to lack of power
(Supplementary Fig. 25). Heterozygous carriers of PDE3B PTVs
showed 0.647 kg m−2 higher BMI (p= 2.09 × 10−4) than the
average UK Biobank participant (Supplementary Fig. 26).
Functional follow-up of candidate genes in adipocyte models.
We sought to illustrate the potential application of DeGAs in
prioritizing candidate genes using functional follow-up experi-
ments. Several of our most interesting ﬁndings were observed
from strong associations between PTVs and obesity-related traits.
Variants in GPR151 and PDE3B are the two strongest con-
tributors, albeit in opposite directions, to the top component
(PC1) driving the genetic associations between PTVs and BMI
(Fig. 4a–c). In addition to BMI, a simple indicator of overall body
fat level, PheWAS studies have suggested strong correlations
between regional body fat distribution and these two PTVs, with
GPR151 being more considerably associated with waist cir-
cumference and trunk fat (Fig. 4d), while PDE3B was more
notably related to hip circumference and lower-body fat (Sup-
plementary Fig. 24). Regional fat deposition is more accurately
reﬂected by the local development and function of adipocytes in
terms of size, number and lipid content. In order to explore how
these two candidates regulate body fat composition differently, we
chose to study their impacts on biological characteristics of adi-
pocytes. Speciﬁcally, the expression and function of PDE3B and
GPR151 were evaluated in mouse 3T3-L1 and human Simpson-
Golabi-Behmel Syndrome (SGBS) cells, two well-established
preadipocyte models used for studying adipocyte differentiation
(i.e. adipogenesis) and function36,37.
First, we demonstrated that both genes were expressed in
preadipocytes, but showed different expression patterns when
cells were transforming into mature adipocytes: PDE3B increased
dramatically during both mouse and human adipogenesis, while
GPR151 maintained a low expression level throughout the
differentiation (Fig. 5a, b). Next, to explore the causal relation-
ships between gene expression and adipogenesis, we introduced
short interfering RNA (siRNA) against Pde3b and Gpr151,
respectively, into 3T3-L1 preadipocytes and monitored the
impact of gene knockdown on conversion of preadipocytes to
adipocytes. Knockdown of Gpr151, by 3 siRNAs individually and
together (Fig. 5c), drastically impaired adipocyte differentiation,
as evidenced by lowered expression of adipogenesis markers
(Pparg, Cebpa, and Fabp4) (Fig. 5d), as well as the reduced
formation of lipid-containing adipocytes (Fig. 5e, f). Further, to
test the functional capacity of the fat cells lacking Gpr151, we
performed a lipolysis assay — an essential metabolic pathway of
adipocytes and thus, a key indicator of adipocyte function — on
mature adipocytes derived from preadipocytes transfected with
either scrambled siRNA (scRNA) or siGpr151. Not surprisingly,
Gpr151-deﬁcient lipid-poor adipocytes showed dramatically
lower lipolysis, along with the impaired capability of responding
Fig. 3 The top three key DeGAs components for BMI, MI, and gallstones. a The top three key components for each phenotype are identiﬁed by phenotype
squared cosine scores and characterized with the driving phenotypes by phenotype contribution scores (Methods). Each colored segment represents a
phenotype with at least 0.5% of phenotype contribution scores for each of the component and the rest of the phenotypes are aggregated as others and
shown as the gray bar on the top. For BMI, additional phenotype grouping is applied (Methods, Supplementary Table 2). b Biological characterization of
driving non-coding and coding variants of the key components for BMI with GREAT. The key components are shown proportional to their squared cosine
score along with signiﬁcantly enriched terms in mouse MGI phenotype ontology. The radius represents binomial fold change and the color gradient
represents −log10(p-value) from GREAT ontology enrichment analysis. pred.: predicted, #: number, %: percentage, mass/% mass and percentage, BP:
blood pressure, AR: automated reading, L: left, R: right, WA: weighted average. †: Corneal resistance factor (right), ‡: Birth weight of ﬁrst child, §: Age
started wearing glasses or contact lenses, ||: Average weekly beer plus cider intake, ¶: Median z-statistic (in group-deﬁned mask) for shapes activation, ♣:
Weighted-mean MD in tract uncinate fasciculus (right). Source data are provided in Supplementary Data 2-3
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to isoproterenol (ISO), a β-adrenergic stimulus of lipolysis (Fig.
5g). These data suggest that GPR151 knockdown in adipocyte
progenitor cells may block their conversion into mature
adipocytes.
To further analyze the functional impact of GPR151 in
adipocytes, we generated an overexpression model of GPR151
by infecting 3T3-L1 preadipocytes with virus expressing Flag-
tagged human GPR151 driven by either EF1α or aP2 promotor
(Supplementary Fig. 27a). Overexpression of GPR151 by both
constructs were conﬁrmed at the gene and protein levels
(Supplementary Fig. 27b–d). However, despite the substantial
effect of Gpr151 knockdown on adipogenesis (Fig. 5), over-
expression of GPR151 in preadipocytes failed to inﬂuence
adipocyte differentiation signiﬁcantly, as shown by similar levels
of adipogenic markers compared to the non-infected controls
(Supplementary Fig. 27e, f). To eliminate the potential masking
effects of any unperturbed cells in the partially infected cell
population, we speciﬁcally selected GPR151-overexpressing cells
by staining Flag-GPR151 positive cells with APC-conjugated ﬂag
antibody and sorted APC+ and APC− cells from the
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differentiating adipocyte cultures (Supplementary Fig. 27g–l). In
both EF1α- and aP2-driven GPR151 overexpression models,
GPR151 mRNA levels were enriched in APC+ cells compared to
APC- cells (Supplementary Fig. 27m–n). However, APC+ cells
expressed genes characteristics of differentiating adipocytes in a
similar level to that of APC− cells (Supplementary Fig. 27m–n).
These data conclude that overexpression of GPR151 in
preadipocytes cannot further enhance adipogenesis, suggesting
that the endogenous level of GPR151 in preadipocytes may be
sufﬁcient to maintain the normal differentiation potential of
preadipocytes. Although GPR151 is predominantly expressed in
the brain, especially in hypothalamic neurons that control
appetite and energy expenditure38, we identiﬁed that the
GPR151 protein is present in both subcutaneous and visceral
adipose tissue from mice (SAT and VAT), albeit in a very low
level (Supplementary Fig. 27o). To sum up the results from the
gain- and loss-of-function studies of GPR151 in preadipocyte
models, minimal but indispensable endogenous expression of
GPR151 in adipose progenitor cells in generating lipid-rich
adipocytes may underlie one of the mechanisms by which
GPR151 promotes obesity.
In contrast to GPR151, knockdown of Pde3b in 3T3-L1
preadipocytes (Supplementary Fig. 28a) showed no signiﬁcant
inﬂuence on adipogenesis and lipolysis (under either basal or β-
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adrenergic stimulated conditions), as compared to scRNA-
transfected controls (Supplementary Fig. 28b–e). Since PDE3B
is expressed primarily in differentiated adipocytes (Fig. 5a, b),
future research efforts should be concentrated on studying the
metabolic role of PDE3B in mature adipocytes.
Collectively, we performed functional characterization studies
on the top two genes contributing to obesity-related traits, as
selected based on the DeGAs approach in an unbiased manner, in
hopes of (1) providing an example of how to interpret the results
from DeGAs effectively and how to select candidate genes for the
relevant experimental models; and (2) initiating an application of
DeGAs in biological research and inspiring more state-of-art
translational studies of candidates predicted from DeGAs.
Discussion
We developed DeGAs, an application of TSVD, to decompose
genome-and phenome-wide summary statistic matrix from
association studies of thousands of phenotypes for systematic
characterization of latent components of genetic associations and
advanced the understanding on polygenic and pleiotropic archi-
tecture of complex traits. Applying DeGAs, we identiﬁed key
latent components characterized with disease outcomes, risk
factors, comorbidity structures, and environmental factors, with
corresponding sets of genes and variants, providing insights on
their context-speciﬁc functions. We demonstrated the robustness
of the results by applying DeGAs with different parameters. With
additional biological characterization of latent components using
GREAT, we ﬁnd component-speciﬁc enrichment of relevant
phenotypes in mouse phenotype ontology. This replication across
species highlights the ability of DeGAs to capture functionally
relevant sets of both coding and non-coding variants in each
component.
Our comparison of DeGAs to an alternative approach —
decomposition of individual phenotype data followed by GWAS
— highlights the ability of DeGAs to capture most of the variation
in the genetic associations and to enable identiﬁcation of bio-
medically relevant genetic signals as latent components con-
necting sets of genetic variants and phenotypes. As an illustration
of in-depth analysis of genetic variants with different functional
consequences, we reported applications of DeGAs for different
functional categories.
In DeGAs, we provided multiple ways to investigate the bio-
logical relevance of latent components, including quantitative
scores and ontology enrichment analysis. These metrics are useful
to annotate and interpret latent components, which are otherwise
just mathematical objects in a high-dimensional space. For
example, we found a signiﬁcant contribution of anthropometric
traits among the top 5 components, which reﬂects the pervasive
polygenicity of these traits (Supplementary Fig. 29)39,40. By
leveraging the ability of TSVD to efﬁciently summarize most of
the variance in the input association statistic matrix, DeGAs
provides a systematic way to interpret polygenic and pleiotropic
genetic architecture of common complex traits.
Given that DeGAs is applied to summary statistics and does
not require individual-level data, there is substantial potential to
dissect genetic components of the human phenome when applied
to data from population-based biobanks around the globe14,41–44.
In fact, we are the ﬁrst to develop a computational method that
can jointly analyze genetics of thousands of phenotypes from a
densely phenotyped population. As a proof of concept, we
demonstrate a strategy to identify candidate genes for transla-
tional studies for obesity or its complications based on combi-
nation of quantitative results from DeGAs, phenome-wide
analyses in the UK Biobank, and functional studies in adipocytes.
Due to differences in phenotype and variant selection, it is
possible that the latent structures discovered from DeGAs would
be different if using GWAS summary statistics from a different
GWAS study. However, DeGAs is capable of identifying the most
relevant components for a given input dataset using quantitative
scores. In fact, our analysis for the three datasets — “all”, coding,
and PTVs— identiﬁed different PCs for each trait of our interest,
but their characterization with contribution scores enabled
interpretation of the DeGAs components.
To select candidate genes and their most relevant experimental
models for the functional studies in an unbiased manner, we
applied DeGAs to PTVs dataset. First, we identiﬁed PC1 as the
top phenotype contribution component to BMI. Second, based on
the fact that the main drivers of PC1 phenotypes were fat mass-
related measurements, we chose adipocytes as our experimental
model to approach candidate gene studies. Last but not least, we
unbiasedly selected the top two genes contributing PTVs to PC1
(variants in GPR151 and PDE3B) and explored their functionality
in fat cells, in order to illustrate the application of DeGAs com-
putational analysis in biological research.
As a result, loss-of-function of GPR151 in adipocyte precursors
limited their conversion into lipid-rich adipocytes. This result is
directionally consistent with our DeGAs and univariate regres-
sion analysis showing that GPR151 PTVs are associated with
lower obesity and fat mass, especially central obesity (e.g., waist
circumference and trunk fat mass) (Fig. 4d). GPCRs are known to
inﬂuence adipogenesis by conveying a complex series of sec-
ondary messengers, including cAMP and calcium signals45,46.
The density of receptors and the timing of receptor expression
during adipogenesis governs the level, timing, and duration of the
secondary signals, which is a critical factor in initiating and/or
maintaining adipocyte conversion45. Although the endogenous
expression of GPR151 is low in preadipocytes, our results show
that its presence is important to instigate the early events of
adipogenic differentiation. Further investigation of the mechan-
ism of GPR151 action is valuable to understand its integral role in
adipogenesis to the full extent.
PDE3B, on the other hand, did not affect differentiation of
preadipocytes signiﬁcantly in our study. There is evidence that
PDE3B plays a more notable role in differentiated mature adi-
pocytes, the primary component of adipose tissue. As an essential
enzyme that hydrolyzes both cAMP and cGMP, PDE3B is known
to be predominantly expressed in tissues that are important in
regulating energy homeostasis, including adipose tissue47. White
adipose tissue in Pde3b knockout mice behaves more as “beige”
fat with improved mitochondrial activity and energy-burning
properties, leading to a reduction of visceral fat mass as compared
to the wild-type littermates48. Moreover, Pde3b knockout in mice
confers cardioprotective effects49, and human PDE3B “knockout”
subjects display lower circulating triglycerides and higher HDL-
cholesterol in blood50. There is a growing body of evidence that
cardiometabolic health is linked to improved body fat distribution
(i.e. lower visceral fat, higher subcutaneous fat)51. Our PheWAS
analysis suggests that PDE3B PTVs have the strongest association
to hip circumference (e.g., lower-body subcutaneous adiposity)
(Supplementary Fig. 24). Therefore, understanding the fat depot-
speciﬁc metabolic effects of PDE3B may help uncover the
mechanism underlying the positive relationship of PDE3B PTVs
with peripheral fat accumulation and favorable metabolic proﬁles.
Taken together, we highlight the directional concordance of
our experimental data with the quantitative results from DeGAs
and PTV-phenotype associations: GPR151 inhibition may reduce
total body and central fat, while deletion of PDE3B may favor
subcutaneous, rather than visceral, fat deposition; both are
expected to have beneﬁcial effects on cardiometabolic health.
Although these two genes were recently reported to be associated
with obesity in another recent study based on the UK Biobank52,
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we are the ﬁrst to experimentally identify a requisite role of
GPR151 in regulating adipogenesis. We also suggest a role of
PDE3B in mature adipocytes to impose the cardioprotective
effects of PDE3B inhibitors49. In this study, we focused on eval-
uating the functional effects of these genes on adipocyte function
and development. We do not exclude the contribution nor the
importance of other tissues or mechanisms underlying body
weight changes. Indeed, some lines of evidence support additional
effects of GPR151 on obesity via the central nervous system —
possibly on appetite regulation38, while loss-of-function in
PDE3B is also associated with height52 — another contributing
factor to body weight changes.
The resource made available with this study, including the
DeGAs app, an interactive web application in the Global Biobank
Engine53, provides a starting point to investigate genetic com-
ponents, their functional relevance, and potential therapeutic
targets. These results highlight the beneﬁt of comprehensive
phenotyping on a population and suggest that systematic char-
acterization and analysis of genetic associations across the human
phenome will be an important part of efforts to understand
biology and develop therapeutic approaches.
Methods
Compliance with ethical regulations and informed consent. This research has
been conducted using the UK Biobank Resource under Application Number 24983,
“Generating effective therapeutic hypotheses from genomic and hospital linkage
data” (http://www.ukbiobank.ac.uk/wp-content/uploads/2017/06/24983-Dr-
Manuel-Rivas.pdf). Based on the information provided in Protocol 44532 the
Stanford IRB has determined that the research does not involve human subjects as
deﬁned in 45 CFR 46.102(f) or 21 CFR 50.3(g). All participants of UK Biobank
provided written informed consent (more information is available at https://www.
ukbiobank.ac.uk/2018/02/gdpr/). All DNA samples and data in this study were
pseudonymized.
Study population. The UK Biobank is a population-based cohort study collected
from multiple sites across the United Kingdom. Information on genotyping and
quality control has previously been described14. In brief, study participants were
genotyped using two similar arrays (Applied Biosystems UK BiLEVE Axiom Array
(807,411 markers) and the UK Biobank Axiom Array (825,927 markers)), which
were designed for the UK Biobank study. The initial quality control was performed
by the UK Biobank analysis team and designed to accommodate the large-scale
dataset of ethnically diverse participants, genotyped in many batches, using two
similar arrays14.
Genotype data preparation. We used genotype data from the UK Biobank dataset
release version 214 and the hg19 human genome reference for all analyses in the
study. To minimize the variabilities due to population structure in our dataset, we
restricted our analyses to include 337,199 White British individuals based on the
following ﬁve criteria reported by the UK Biobank in the ﬁle “ukb_sqc_v2.txt”:
1. self-reported white British ancestry (“in_white_British_ancestry_subset”
column)
2. used to compute principal components (“used_in_pca_calculation” column)
3. not marked as outliers for heterozygosity and missing rates (“het_missin-
g_outliers” column)
4. do not show putative sex chromosome aneuploidy (“putative_sex_chromo-
some_aneuploidy” column)
5. have at most 10 putative third-degree relatives (“excess_relatives” column).
We annotated variants using the VEP LOFTEE plugin (https://github.com/
konradjk/loftee) and variant quality control by comparing allele frequencies in the
UK Biobank and gnomAD version 2.0.1 (gnomad.exomes.r2.0.1.sites.vcf.gz)12,54.
We focused on variants outside of major histocompatibility complex (MHC)
region (chr6:25477797-36448354) based on the Genome Reference Consortium
GRCh37 deﬁnition55 and performed LD pruning using PLINK56 with “--indep 50 5
2”. Furthermore, we selected variants according to the following rules:
● Missingness of the variant is less than 1%.
● Minor-allele frequency is greater than 0.01%.
● The variant is in the LD-pruned set.
● Hardy-Weinberg disequilibrium test p-value is greater than 1.0 × 10−7.
● Manual cluster plot inspection. We investigated cluster plots for subset of our
variants and removed 11 variants that have unreliable genotype calls12.
● Passed the comparison of minor allele frequency with gnomAD dataset12,54.
These variant ﬁlters are summarized in Supplementary Fig. 1.
Phenotype data preparation. We organized 2,138 phenotypes from the UK
Biobank14 in 11 distinct groups (Supplementary Table 1, Supplementary Data 1).
We included phenotypes with at least 100 cases for binary phenotypes and 100
individuals with non-missing values for quantitative phenotypes. We used phe-
notype deﬁnitions from a previously published paper12. Brieﬂy, a combination of
cancer diagnoses from the UK Cancer Register with self-reported diagnoses, a
combination of disease diagnoses from the UK National Health Service Hospital
Episode Statistics with self-reported diagnoses, and the UK Biobank phenotype
category 100034 (Family history–Touchscreen–UK Biobank Assessment Centre)
were used for disease outcomes, cancer phenotypes, and family history deﬁnitions,
respectively12. We also used additional data ﬁelds and data category from the UK
Biobank14 to deﬁne the phenotypes in the following categories as well as 19 and 42
additional miscellaneous binary and quantitative phenotypes: medication, imaging,
physical measurements, assays, and binary and quantitative questionnaire Sup-
plementary Table 1, Supplementary Data 1).
Some phenotype information from the UK Biobank contains three instances,
each of which corresponds to (1) the initial assessment visit (2006–2010), (2) ﬁrst
repeat assessment visit (2012–2013), and (3) imaging visit (2014–). For binary
phenotype, we deﬁned "case" if the participants are classiﬁed as case in at least one
of their visits and "control" otherwise. For quantitative phenotype, we took a
median of non-NA values. In total, we deﬁned 1,196 binary phenotypes and 943
quantitative phenotypes.
Genome-wide association analyses of 2,138 phenotypes. Association analyses
for single variants were applied to the 2,138 phenotypes separately. We used the
following covariates in our GWAS analyses: age, sex, array type, and the ﬁrst four
genetic principal components provided by UK Biobank in the sample QC ﬁle14,
where the array type indicates if a participant was genotyped with UK Biobank
Axiom Array or UK BiLEVE Axiom Array. For binary phenotypes, we performed
Firth-fallback logistic regression using PLINK v2.00a (17 July 2017)12,56. For
quantitative phenotypes, we applied generalized linear model association analysis
with PLINK v2.00a (20 Sep. 2017)56. We applied quantile normalization for phe-
notype (--pheno-quantile-normalize option), where we ﬁt a linear model with
covariates and transform the phenotypes to normal distribution N(0,1). while
preserving the original rank. We used the following covariates in our analysis: age,
sex, types of genotyping array, and the ﬁrst four genotype principal components
computed from the UK Biobank14.
To test the effects of population stratiﬁcation correction on the association
analysis, we performed additional GWAS with age, sex, types of array, and the ﬁrst
ten genotype principal components as covariates for the ﬁve quantitative traits and
ﬁve binary traits. For each pair of GWAS summary statistics with four and ten
genotype principal components, we computed the genetic correlations and
conﬁrmed that the two GWAS run yielded the almost identical results
(Supplementary Table 5). We used GNU parael in part of our analysis57.
Summary statistic matrix construction and variant ﬁlters. We constructed three
Z-score summary statistic matrices. Each element of the matrix corresponds to
summary statistic for a particular pair of a phenotype and a variant. We imposed
different sets of variant ﬁlters.
● Variant quality control ﬁlter: Our quality control ﬁlter described in the
previous section on genotype data preparation.
● Non-MHC variant ﬁlter: All variants outside of major histocompatibility
complex region. With this ﬁlter, variants in chr6:25477797-36448354 were
excluded from the summary statistic matrix.
● Coding-only: With this ﬁlter, we subset to include only the variants having the
VEP LOFTEE predicted consequence of: missense, stop gain, frameshift, splice
acceptor, splice donor, splice region, loss of start, or loss of stop.
● PTVs-only: With this ﬁlter, we subset to include only the variants having the
VEP LOFTEE predicted consequence of: stop gain, frameshift, splice acceptor,
or splice donor.
By combining these ﬁlters, we deﬁned the following sets of variants
● All-non-MHC: This is a combination of our variant QC ﬁlter and non-MHC
ﬁlter.
● Coding-non-MHC: This is a combination of our variant QC ﬁlter, non-MHC
ﬁlter, and Coding-only ﬁlter.
● PTVs-non-MHC: This is a combination of our variant QC ﬁlter, non-MHC
ﬁlter, and PTVs-only ﬁlter.
In addition to phenotype quality control and variant ﬁlters, we introduced
value-based ﬁlters based on statistical signiﬁcance to construct summary statistic
matrices only with conﬁdent values. We applied the following criteria for the value
ﬁlter:
● P-value of marginal association is less than 0.001.
● Standard error of beta value or log odds ratio is less than 0.08 for quantitative
phenotypes and 0.2 for binary phenotypes.
With these ﬁlters, we obtained the following two matrices:
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● “All-non-MHC” dataset that contains 2,138 phenotypes and 235,907 variants.
We label this dataset as “all” dataset.
● “Coding-non-MHC” dataset that contains 2,064 phenotypes and 16,135
variants. We label this dataset as “Coding only” dataset.
● “PTVs-non-MHC” dataset that contains 628 phenotypes and 784 variants. We
label this dataset as “PTVs only” dataset.
The coding-only and PTVs-only datasets contain a fewer number of phenotypes
because not all the phenotypes have statistically signiﬁcant associations with coding
variants or PTVs. The effects of variant ﬁlters are summarized in Supplementary
Fig. 1. Finally, we transformed the summary statistics to Z-scores so that each
vector that corresponds to a particular phenotype has zero mean with unit
variance.
TSVD of the summary statistic matrix. For each summary statistic matrix, we
applied truncated singular value decomposition (TSVD). The matrix, which we
denote as W, of size N ×M, where N denotes the number of phenotypes and M
denotes the number of variants, is the input data. With TSVD, W is factorized into
a product of three matrices: U, S, and VT: W=USVT, where U= (ui,k)i,k is an
orthonormal matrix of size N × K whose columns are phenotype (left) singular
vectors, S is a diagonal matrix of size K × K whose elements are singular values, and
V= (vj,k)j,k is an orthonormal matrix of size M × K whose columns are variant
(right) singular vectors. While singular values in S represent the magnitude of the
components, singular vectors in U and V summarize the strength of association
between phenotype and component and variant and component, respectively. With
this decomposition, the k-th latent component (principal component, PC k) are
represented as a produ of k-th column U, k-th diagonal element in S, and k-th row
of VT. For TSVD on the summary statistics, we used implicitly restarted Lanczos
bidiagonalization algorithm (IRLBA)58 (https://github.com/bw.ewis/lba) imple-
mented on SciDB59 to compute the ﬁrst K components in this decomposition.
Relative variance explained by each of the components. A scree plot (Sup-
plementary Fig. 2) quantify the variance explained by each component: variance
explained by k-th component= sk2/VarTot(W) where, sk is the k-th diagonal ele-
ment in the diagonal matrix S and VarTot(W) is the total variance of the original
matrix before DeGAs is applied.
Selection of number of latent components in TSVD. In order to apply TSVD to
the input matrix, the number of components should be speciﬁed. We apply K=
100 for our analysis for all of the datasets. Following a standard practice of keeping
components with eigenvalues greater than the average24, we ﬁrst computed the
expected value of squared eigenvalues under the null model where the distribution
of variance explained scores across the full-ranks are uniform. This can be com-
puted with the rank of the original matrix, which is equal to the number of
phenotypes in our datasets:
E Variance explained by kth component under the null½ 
¼ 1= Rank Wð Þ2  ð1Þ
We then compared the eigenvalues characterized from TSVD with the expected
value. For all of the three datasets, we found that that of 100-th component is
greater than the expectation. This indicates even the 100-th components are
informative to represent the variance of the original matrix. In the interest of
computational efﬁciency, we set K= 100.
To demonstrate the robustness of the DeGAs components with respect to the
number of latent components (K), we performed additional analyses with K= 90
and K= 110, and investigated the ﬁrst ﬁve latent components as well as the top
three components for the three phenotypes of our interest.
Factor scores. From these decomposed matrices, we computed factor score
matrices for both phenotypes and variants as the product of singular vector matrix
and singular values. We denote the one for phenotypes as Fp ¼ f pi;j
 
i;j
the one for
variants as Fv ¼ f vi;j
 
i;j
and deﬁned as follows:
Fp ¼ US ð2Þ
Fv ¼ VS ð3Þ
Since these factor scores are mathematically the same as principal components
in principal component analysis (PCA), one can investigate the contribution of the
phenotypes or variants for speciﬁc principal components by simply plotting factor
scores24 (Fig. 2a, b). Speciﬁcally, phenotype factor score is the same as phenotype
principal components and variant factor score is the same as variant principal
components. By normalizing these factor scores, one can compute contribution
scores and cosine scores to quantify the importance of phenotypes, variants, and
principal components as described below.
Scatter plot visualization with biplot annotations. To investigate the relation-
ship between phenotype and variants in the TSVD eigenspace, we used a variant of
biplot visualization60,61. Speciﬁcally, we display phenotypes projected on
phenotype principal components (Fp=US) as a scatter plot. We also show variants
projected on variant principal components (Fv=VS) as a separate scatter plot and
added phenotype singular vectors (U) as arrows on the plot using sub-axes (Figs.
2b, 4c, Supplementary Figs. 10–11). In scatter plot with biplot annotation, the inner
product of a genetic variant and a phenotype represents the direction and the
strength of the projection of the genetic association of the variant-phenotype pair
on the displayed latent components. For example, when a variant and a phenotype
share the same direction on the annotated scatter plot, that means the projection of
the genetic associations of the variant-phenotype pair on the displayed latent
components is positive. When a variant-phenotype pair is projected on the same
line, but on the opposite direction, the projection of the genetic associations on the
shown latent components is negative. When the variant and phenotype vectors are
orthogonal or one of the vectors are of zero length, the projection of the genetic
associations of the variant-phenotype pair on the displayed latent components is
zero. Given the high dimensionality of the input summary statistic matrix, we
selected relevant phenotypes to display to help the interpretation of genetic asso-
ciations in the context of these traits.
Contribution scores. To quantify the contribution of the phenotypes, variants, and
genes to a given component, we computed contribution scores. We ﬁrst deﬁned
phenotype contribution score and variant contribution score. We denote pheno-
type contribution score and variant contribution score for some component k as
cntrphek ið Þ and cntrvark jð Þ, respectively. They were deﬁned by squaring the left and
right singular vectors and normalizing them by Euclidean norm across phenotypes
and variants:
cntrphek ið Þ ¼ ui;k
 2 ð4Þ
cntrvark jð Þ ¼ vi;k
 2 ð5Þ
where, i and j denote indices for phenotypand variant, respectively. Because U and
V are orthonormal, the sum of phenotype and variant contribution scores for a
given component are guaranteed to be one, i.e.
P
i cntr
phe
k ið Þ ¼
P
j cntr
var
k jð Þ ¼ 1.
Based on the variant contribution scores for the k-th component, we deﬁned the
gene contribution score for some component k as the sum of variant contribution
scores for the set of variants in the gene:
cntrgenek gð Þ ¼
P
j2g
cntrvark jð Þ ð6Þ
where, g denotes indices for the set of variants in gene g. To guarantee that gene
contribution scores for a given component sum up to one, we treated the variant
contribution score for the non-coding variants as gene contribution scores. When
multiple genes, g1, g2, …, gn are sharing the same variants, we deﬁned the gene
contribution score for the intersection of multiple genes rather than each gene:
cntrgenek giji 2 ½1; nf gð Þ ¼
P
j j2g1^j2g2^^j2gnjf g
cntrvark jð Þ ð7Þ
With these contribution scores for a given component, it is possible to quantify
the relative importance of a phenotype, variant, or gene to the component. Since
DeGAs identiﬁes latent components using unsupervised learning, we interpret each
component in terms of the driving phenotypes, variants, and genes, i.e. the ones
with large contribution scores for the component.
The top 20 driving phenotypes, variants, and genes (based on contribution
scores) for the top ﬁve TSVD components and the top three key components for
our phenotypes of interest are summarized in Supplementary Table 2.
We used stacked bar plots for visualization of the contribution score proﬁle for
each of the components. We represent phenotypes, genes, or variants with large
contribution scores as colored segments and aggregated contributions from the
remaining ones as “others” in the plot (Figs. 2c, d, 3a, 4a, b, Supplementary Fig. 4).
To help interpretation of the major contributing factors for the key components, we
grouped phenotypes into categories, such as “fat”, “fat-free” phenotypes, and showed
the sum of contribution scores for the phenotype groups. The list of phenotype
groups used in the visualization is summarized in Supplementary Table 2.
Squared cosine scores. Conversely, we can also quantify the relative importance
of the latent components for a given phenotype or variant with squared cosine
scores. We denote phenotype squared cosine score for a given phenotype i and
variant squared cosine score for a given variant j as cos2
phe
i kð Þ and cos2
var
j kð Þ,
respectively. They are deﬁned by squaring of the factor scores and normalizing
them by Euclidean norm across components:
cos2
phe
i kð Þ ¼ f pi;k
 2
=
X
k0
f pi;k0
 2 ð8Þ
cos2
var
j kð Þ ¼ f vj;k
 2
=
X
k0
f vj;k0
 2 ð9Þ
By deﬁnition, the sum of squared cosine scores across a latent component for a
given phenotype or variant equals to one, i.e.
P
k cos
2phe
i kð Þ ¼
P
k cos
2var
j kð Þ. While
singular values in the diagonal matrix S quantify the importance of latent
components for the global latent structure, the phenotype or variant squared cosine
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score quantiﬁes the relative importance of each component in the context of a
given phenotype or a variant. The squared cosine scores for the phenotypes
highlighted in the study is summarized in Supplementary Figs. 3 and 9.
Note that squared cosine scores and contribution scores are two complementary
scoring metrics to quantify the relationship among phenotypes, components,
variants, and genes. It does not necessarily have the inverse mapping property. For
example, it is possible to see a situation, where for a given phenotype p, phenotype
squared cosine score identiﬁes k as the top key component, but phenotype
contribution score for k identiﬁes p′ (p′ ≠ p) as the top driving phenotype for the
component k. This is because the two scores, contribution score and squared cosine
score, are both deﬁned by normalizing singular vector and principal component
vector matrices, respectively, but with respect to different slices: one for row and
the other for column.
TSVD of the individual-level phenotypes. To characterize the latent components
in the raw phenotype data, we ﬁrst applied median imputation for missinge values
on the phenotype data followed by Z-score transformation. Using Python scikit-
learn package62, we applied TSVD on the imputed and normalized phenotype
matrix and characterized the ﬁrst ﬁve latent components and visualized the scree
plot as well as the phenotype and individual PCs in scatter plots.
Genome-wide-association analysis for phenotype PCs. Using the results of the
phenotype decomposition described above, we deﬁned principal components of the
individual’s phenotype (phenotype PCs) and applied genome-wide association
analysis using the same procedure we used for the original quantitative traits. We
used R package qqplot to generate Manhattan plot63.
Genetic correlation of phenotype PCs. To compare the results of association
analysis of phenotype PCs, we computed genetic correlation using LD score
regression64. We summarized the estimated genetic correlation (rg) as heatmap and
characterized the median value of absolute value of rg among the top k phenotype
PCs as a function of k.
Genomic region enrichment analysis with GREAT. We applied the genomic
region enrichment analysis tool (GREAT version 4.0.3) to each DeGAs
components20,21. We used the mouse genome informatics (MGI) phenotype
ontology, which contains manually curated knowledge about hierarchical structure
of phenotypes and genotype-phenotype mapping of mouse33. We downloaded
their ontologies on 2017-09-28 and mapped MGI gene identiﬁers to Ensembl
human gene ID through unambiguous one-to-one homology mapping between
human and mouse Ensembl IDs. We removed ontology terms that were labeled as
“obsolete”, “bad”, or “unknown” from our analysis. As a result, we obtained
709,451 mapping annotation spanning between 9,592 human genes and 9,554
mouse phenotypes.
For each DeGAs component, we selected the top 5,000 variants according to
their variant contribution score and performed enrichment analysis with the
default parameters20,21. Since we included the non-coding variants in the
analysis, we focused on GREAT binomial genomic region enrichment analysis
based on the size of regulatory domain of genes and quantiﬁed the signiﬁcance of
enrichment in terms of binomial fold enrichment and binomial p-value. Given
that we have 9,554 terms in the ontology, we set a Bonferroni-corrected p-value
threshold of 5 × 10−6.
To illustrate the results of the genomic region enrichment analysis for the
phenotypes of our interest, we made circular bar plots using the R package
ggplot265, where each of the key components are displayed in the innermost track
with their phenotype squared cosine score to be proportional to their angle, and the
resulted signiﬁcant ontology terms are represented as the bars. To focus on the
signiﬁcant signals with large effect size, we imposed additional ﬁlter of binomial
fold ≥2.0 and binomial p-value threshold of 5 × 10−7, The binomial fold change
is represented as the radius and the binomial p-value is represented as color
gradient in a log scale in the plot (Fig. 3b, Supplementary Figs. 7-8, Supplementary
Data 3–5).
Speciﬁcity analysis of GREAT enrichment. To test the speciﬁcity of the GREAT
enrichment of each of the 100 DeGAs components, we computed Jaccard index
similarity scores. For each DeGAs latent component, we looked at the GREAT
enrichment and took the top ﬁve enriched terms sorted by GREAT binomial fold.
To measure the similarity between these enriched terms, we identiﬁed the set of
genes annotated for those terms and computed Jaccard index deﬁned below:
Similarity term setA; term setBð Þ
¼ Gene set term setAð Þ \Gene set term setBð Þj jGene set term setAð Þ ∪ Gene set term setBð Þj j
ð10Þ
where,
Gene set term setAð Þ ¼
[
t2A
Gene set termtð Þ ð11Þ
and Gene set(termt) indicates set of genes annotated with term t. We computed all
the pair-wise similarity across the top k DeGAs components and summarized their
median as a function of k.
Quality control of variant calling with intensity plots. To investigate the quality
of variant calling for the two PTVs highlighted in the study, we manually inspected
intensity plots. These plots are available on Global Biobank Engine.
https://biobankengine.stanford.edu/intensity/rs114285050
https://biobankengine.stanford.edu/intensity/rs150090666
Phenome-wide association analysis. To explore the functional roles of the two
PTVs across thousands of potentially correlated phenotypes, we performed a
phenome-wide association study (PheWAS). We report the statistically signiﬁcant
(p < 0.001) associations with phenotypes with at least 1000 case count or 1000
individuals with measurements with non-missing values for binary and quantita-
tive phenotypes, respectively (Fig. 3d, Supplementary Fig. 10). The results of this
PheWAS are also available as interactive plots as a part of Global Biobank Engine.
https://biobankengine.stanford.edu/variant/5-145895394
https://biobankengine.stanford.edu/variant/11-14865399
Univariate regression analysis for the identiﬁed PTVs. To quantify the effects
of the two PTVs on obesity, we performed univariate regression analysis. We
extracted individual-level genotype information for the two PTVs with the PLINK2
pgen Python API (http://www.cog-genomics.org/plink/2.0/)56. After removing
individuals with missing values for BMI and genotype, we performed linear
regression for BMI (http://biobank.ctsu.ox.ac.uk/crystal/ﬁeld.cgi?id=21001) with
age, sex, and the ﬁrst four genomic PCs as covariates:
BMI  0þ ageþ as:factorðsexÞ þ PC1þ PC2þ PC3
þ PC4þ as:factorðPTVÞ ð12Þ
where, PC1-4 denotes the ﬁrst four genomic principal components, PTV ranges in
0, 1, or 2 and it indicates the number of minor alleles that the individuals have.
The polygenicity analysis and phenotype contribution scores. To quantify the
polygenicity of phenotypes, we applied LD clumping procedure to select and count
independent set of SNPs associated with the trait using PLINK v1.90b6.7 (2
December 2018)56 with --clump --clump-p1 1e-4. We compared the number of
independent associations (clumped “hits”) with the DeGAs contribution scores and
summarized as scatter plots (Supplementary Fig. 29).
Mouse 3T3-L1 cell culture and differentiation. 3T3-L1 preadipocytes were
obtained from ATCC (Catalogue # CL-173™) and cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) and antibiotics
(100 UmL−1 of penicillin G and 100 μg mL−1 of streptomycin) at 37 °C in a
humidiﬁed atmosphere containing 5% CO2. To obtain fully differentiated adipo-
cytes, 3T3-L1 preadipocytes were grown into 2-day post-conﬂuence, and then
differentiation was induced by using a standard differentiation cocktail containing
0.5 mM of IBMX, 1 μM of dexamethasone, 1 μg mL−1 of insulin, and 10% FBS.
After 48 h, medium was changed into DMEM supplemented with 10% FBS and
1 μg mL−1 of insulin and replenished every 48 h for an additional 6 days.
Human SGBS cell culture and differentiation. SGBS cells, a gift from Dr. Martin
Wabitsch (Univ. of Ulm, Germany), were cultured in DMEM/F12 containing
33 μM biotin, 17 μM pantothenate, 0.1 mg mg−1 streptomycin and 100 UmL−1
penicillin (0F medium) supplemented with 10% FBS in a 5% CO2 incubator. To
initiate differentiation, conﬂuent cells were stimulated by 0F media supplemented
with 0.01 mgmL−1 human transferrin, 0.2 nM T3, 100 nM cortisol, 20 nM insulin,
250 μM IBMX, 25 nM dexamethasone and 2 μM rosiglitazone. After day 4, the
differentiating cells were kept in 0F media supplemented with 0.01 mgmL−1
human transferrin, 100 nM cortisol, 20 nM insulin and 0.2 nM T3 for additional
8–10 days until cells were fully differentiated.
siRNA knockdown in 3T3-L1 preadipocytes. At 80% conﬂuence, 3T3-L1 pre-
adipocytes were transfected with 50 nM siRNA against Gpr151 (Origene
#SR413989, 3 unique siRNA duplexes), Pde3b (Origene #SR422062, 3 unique
siRNA duplexes), or scrambled negative control (Origene #SR30004) using Lipo-
fectamine™ RNAiMAX Transfection Reagent (Invitrogen) following the manu-
facturer’s protocol. The 3 siRNAs against the same target were diluted in a 1:1:1
ratio to reach the total concentration of 50 nM, when transfecting as a pool. The
transfected cells were incubated for 48 h and then subjected to differentiation.
Reverse transcription (RT) and qPCR analysis. Total RNA was extracted using
TRIzol reagent (Invitrogen), following the manufacturer’s instruction. RNA was
converted to cDNA using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Quantitative PCR reactions were prepared with TaqMan™
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Fast Advanced Master Mix (Thermo Fisher Scientiﬁc) and performed on ViiA 7
Real-Time PCR System (Thermo Fisher Scientiﬁc). All data were normalized to the
content of Cyclophilin A (PPIA), as the endogenous control. TaqMan primer
information for RT-qPCR is listed below: GPR151 (Hs00972208_s1), Gpr151
(Mm00808987_s1), PDE3B (Hs00265322_m1), Pde3b (Mm00691635_m1), Pparg
(Mm00440940_m1), Cebpa (Mm00514283_s1), Fabp4 (Mm00445878_m1), PPIA
(Hs04194521_s1), Ppia (Mm02342430_g1).
Oil Red O staining and quantiﬁcation. Cells were washed twice with PBS and
ﬁxed with 10% formalin for 1 h at room temperature. Cells were then washed with
60% isopropanol and stained for 15 min with a ﬁltered Oil Red O solution (mix six
parts of 0.35% Oil Red O in isopropanol with four parts of water). After washing
with PBS 4 times, cells were maintained in PBS and visualized by inverted
microscope. After taking pictures, Oil Red O stain was extracted with 100% iso-
propanol and the absorbance was measured at 492 nm by a multi-well spectro-
photometer (Bio-Rad).
Lipolysis assay. Glycerol release into the culture medium was used as an index of
lipolysis. Fully differentiated 3T3-L1 adipocytes were serum starved overnight and
then treated with either vehicle (DMSO) or the lipolytic stimuli isoproterenol (ISO,
10 µM) for 3 h. The culture medium was collected and the glycerol content in the
culture medium was measured using an adipocyte lipolysis assay kit (ZenBio #LIP-
1-NCL1). Glycerol release into the culture medium was normalized to the protein
content of the cells from the same plate.
Overexpression of GPR151 in 3T3-L1 preadipocytes. The GPR151 construct was
obtained from Addgene (#66327). This construct includes a cleavable HA signal
to promote membrane localization, a FLAG epitope sequence for cell surface
staining followed by codon-optimized human GPR151 sequence66. We PCR-
ampliﬁed the above sequence with stop codon and assembled it into a lentiviral
plasmid (Addgene #85969) with either EF1α promoter (Addgene #11154) or aP2
promoter (Addgene #11424). EF1α-GPR151 or aP2-GPR151 lentiviral plasmid
were transfected into human embryonic kidney 293T cells, together with the
viral packaging vectors pCMV-dR8.91 and pMD2-G. 72 h after transfection,
virus-containing medium was collected, ﬁltered through a 0.45-μm pore-size
syringe ﬁlter, and frozen at −80 °C. 3T3-L1 preadipocytes at 50% conﬂuence
were infected with the lentivirus stocks containing 8 µg mL−1 polybrene. Two
days after transduction, lentivirus-infected 3T3-L1 preadipocytes were subject to
differentiation.
Flow cytometry analysis. Day 6 differentiating 3T3-L1 adipocytes were collected
and washed with ice cold FACS buffer (PBS containing 2% BSA). Cells were ﬁrst
resuspended into FACS staining buffer (BioLegend # 420201) at ~1M cells per 100
μl and incubated with anti-mouse CD16/CD32 Fc Block (BioLegend #101319) at
room temperature for 10–15 min. Cells were then incubated with APC-conjugated
FLAG antibody (BioLegend #637307) for 20–30 min at room temperature in the
dark. Following washing and centrifugation, cells were resuspended in FACS buffer
and sorted using a BD InﬂuxTM Cell Sorter. Cells without FLAG antibody
staining were used to determine background ﬂuorescence levels. Cells were sorted
based on APC ﬂuorescence and collected directly into TRIzol reagent for RNA
extraction.
Western blot analysis. Lysate aliquots containing 50 μg of proteins were dena-
tured, separated on a 4–10% SDS-polyacrylamide gel, and transferred to nitro-
cellulose membranes using a Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad).
Membranes were blocked in 5% non-fat milk and incubated overnight at 4 °C with
primary antibodies: anti-GPR151 (LSBio # LS-B6760-50, 1:500 dilution) or anti-
beta-actin (Cell Signaling #3700, 1:1000 dilution). Subsequently, the membranes
were incubated for 1 h at room temperature with IRDye® 800CW goat-anti-mouse
antibody (LI-COR #926-32210, 1:2500 dilution). Target proteins were visualized
using Odyssey® Fc Imaging System (LI-COR). Uncropped blots were provided in
the Source Data.
Statistical analysis of functional data. Data are expressed as mean ± SEM. Stu-
dent’s t-test was used for single variables, and one-way ANOVA with Bonferroni
post hoc correction was used for multiple comparisons using GraphPad Prism
7 software.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The association analysis data, the interactive DeGAs App, and its video tutorial are
available as a part of Global Biobank Engine (https://biobankengine.stanford.edu/degas).
The decomposed matrices are available on ﬁgshare (https://doi.org/10.35092/
yhjc.9202247). The source data underlying Figs. 2a, b, 4c, and 5 and Supplementary Figs.
27, 28 are provided as a Source Data ﬁle.
Code availability
Analysis scripts and notebooks are available on GitHub (https://github.com/rivas-lab/
public-resources/tree/master/uk_biobank/DeGAs).
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